Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. - Wikidata - awgldk - TriplyDB

Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4.

Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4.

http://www.wikidata.org/entity/Q39778606

about

Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence Insulin Resistance and Endothelial Dysfunction Constitute a Common Therapeutic Target in Cardiometabolic Disorders Anti-atherogenic and anti-inflammatory properties of glucagon-like peptide-1, glucose-dependent insulinotropic polypepide, and dipeptidyl peptidase-4 inhibitors in experimental animals Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control Incretin-Based Therapy for Prevention of Diabetic Vascular Complications DPP4 in Diabetes Exploiting the Pleiotropic Antioxidant Effects of Established Drugs in Cardiovascular Disease Animal models of diabetic macrovascular complications: key players in the development of new therapeutic approaches Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists Endogenous bioactive peptides as potential biomarkers for atherosclerotic coronary heart disease Pathophysiology of Non Alcoholic Fatty Liver Disease Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials Glucagon-like peptide-1 receptor agonist protects against hyperglycemia-induced cardiocytes injury by inhibiting high mobility group box 1 expression Glucagon-like peptide-1 receptor signalling reduces microvascular thrombosis, nitro-oxidative stress and platelet activation in endotoxaemic mice.Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas.Anti-inflammatory effects of exendin-4, a glucagon-like peptide-1 analog, on human peripheral lymphocytes in patients with type 2 diabetes.TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading.The ghrelin gene products and exendin-4 promote survival of human pancreatic islet endothelial cells in hyperglycaemic conditions, through phosphoinositide 3-kinase/Akt, extracellular signal-related kinase (ERK)1/2 and cAMP/protein kinase A (PKA) si Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study Glucose-dependent insulinotropic polypeptide prevents the progression of macrophage-driven atherosclerosis in diabetic apolipoprotein E-null mice.Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation The delay in the development of experimental colitis from isomaltosyloligosaccharides in rats is dependent on the degree of polymerization Exenatide can inhibit calcification of human VSMCs through the NF-kappaB/RANKL signaling pathway.Exendin-4 improves cardiac function in mice overexpressing monocyte chemoattractant protein-1 in cardiomyocytes.Dipeptidyl peptidase IV inhibitor attenuates kidney injury in rat remnant kidney.Diabetes and cardiovascular disease: the potential benefit of incretin-based therapies Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice.Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes The cardiovascular effects of glucagon-like peptide-1 receptor agonists: a trial sequential analysis of randomized controlled trials.Exendin-4 ameliorates oxidized-LDL-induced inhibition of macrophage migration in vitro via the NF-κB pathway Liraglutide attenuates high glucose-induced abnormal cell migration, proliferation, and apoptosis of vascular smooth muscle cells by activating the GLP-1 receptor, and inhibiting ERK1/2 and PI3K/Akt signaling pathways.Exendin-4 protects against post-myocardial infarction remodelling via specific actions on inflammation and the extracellular matrix Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice.Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice.Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins Dipeptidyl-peptidase-4 inhibitor, alogliptin, attenuates arterial inflammation and neointimal formation after injury in low-density lipoprotein (LDL) receptor-deficient mice.Dipeptidyl peptidase-4 inhibitor decreases abdominal aortic aneurysm formation through GLP-1-dependent monocytic activity in mice.Exenatide exerts a potent antiinflammatory effect.Pathophysiological mechanisms involved in non-alcoholic steatohepatitis and novel potential therapeutic targets Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes.

P2860

Q26739999-A366055F-78B2-44AF-AA3C-14D9AA146765 Q26740443-9A7A0163-3186-44A4-93AE-B8CFD89AD3D8 Q26749176-2E3860E8-71D3-4174-B86A-31198939264F Q26750746-EC2D77C8-622D-4E08-BC20-8E656F9171DE Q26765470-4A3FD790-2EB8-4142-BB4A-B2CFC6CD2E91 Q26797335-9569A48F-2C5B-43DB-94E1-13C5DC524F11 Q26801173-94D3DD2E-30F4-40A9-8852-9B3E1626E29E Q26822630-24ACFD4D-2640-4678-A310-3906B66A93A0 Q26823085-615F2788-13CD-44C1-842A-A8422D804ACD Q27010136-EA6A8AF1-5517-4DEF-A15E-3E8E4C6500A5 Q28070011-A4C7EE6F-F0D8-4153-BC52-7A24C1BEB169 Q28081569-B7205A21-BD42-4BE8-B9D8-B228D7AD1D95 Q28570190-A639F71C-1657-4083-906A-D2092E05ADC0 Q33434017-1D5F8FE3-0610-46E8-B6CC-05EDE2ACE108 Q33603384-9F9B2AA1-B0B6-4E74-B729-65F204223994 Q33607642-DBF3084D-3CBE-435A-900A-63995E509AAF Q34094979-93145CE7-E1E1-4B3E-AAA9-E1DB81E091AA Q34122321-1194C3D5-5212-4515-ADDC-D1D3ED0334A3 Q34202922-ACFC5EAC-43CF-4F9D-BEE4-5626C7881A37 Q34247469-65E8ABE7-773B-44A5-8601-CE5CF8AD6F68 Q34405101-9FBE5B3C-3784-40F1-BE76-4F5C9960C7DE Q34500574-D69C0A55-08AF-4A3A-9432-A369B9A60F3B Q34560277-FFABF485-D3B9-493D-8FC2-350BE87012B4 Q34603269-9E2D0755-B9FB-4FED-8602-AF1F59F26BB5 Q34690495-7529F06E-7EC4-4A2A-AF12-3F3E8DB941C6 Q34716791-395ACE95-3DA6-457C-9596-397D6A611F0B Q34718822-05A96E6D-44D5-4D64-B89A-768F0D865D5F Q34994502-0E51D75B-1257-4A5D-BCD5-4CDA7A5A0769 Q35017639-4D2B36E4-B221-4D29-95CC-74D127952594 Q35066447-46F7980B-EFC3-41E8-92D8-473754225D12 Q35082511-E4497B99-015E-46ED-8621-5CCCD17BF919 Q35132702-48173A94-E5B1-4F29-8FA4-54C9ADFF7945 Q35180081-E9AC3AD9-F664-4E16-B50A-CF7B02F24088 Q35201564-03616031-0824-404D-B2FE-0C2345CABB96 Q35249760-D6EC7C79-9B97-4728-AA73-2E45935EA905 Q35353937-F987CD8C-7961-4725-8BA1-61E274C6E8F6 Q35413944-C81D0870-1BAE-4A0A-BE33-7CF492101C71 Q35654205-29353AAC-4795-4B71-B637-282BD286D778 Q35668745-6AE04937-3625-4E86-9957-3F1EB9106183 Q35677365-FF4069E3-65F2-4E1A-AF5A-71D4DF3C9460

P2860

Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4.

http://www.wikidata.org/entity/Q39778606

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh

2010年學術文章

@zh-hant

name

Inhibition of monocyte adhesio ...... 1 receptor agonist, exendin-4.

@en

Inhibition of monocyte adhesio ...... 1 receptor agonist, exendin-4.

@nl

type

label

Inhibition of monocyte adhesio ...... 1 receptor agonist, exendin-4.

@en

Inhibition of monocyte adhesio ...... 1 receptor agonist, exendin-4.

@nl

prefLabel

Inhibition of monocyte adhesio ...... 1 receptor agonist, exendin-4.

@en

Inhibition of monocyte adhesio ...... 1 receptor agonist, exendin-4.

@nl

P1433

Q39778606-3A3E0B8E-2117-4939-A2D5-B340F07F6F70

P1476

Q39778606-630283E9-C266-4BE6-A7AD-48F6E1096ADC

P2093

Q39778606-26E2E9C2-9AAD-48A5-9A05-9BFC4B62D45E

Q39778606-4AD70CB1-9018-404D-8BD8-82D46CB49B37

Q39778606-65936329-3CFA-4D07-9B58-4BEA0CA7C0EA

Q39778606-82642ADA-F14F-4636-B062-EA76865BCB8A

Q39778606-AF7ECDCB-15C9-480E-9525-206F9A1444E9

Q39778606-DD7E513A-17A1-4B53-94D1-6888255A51B1

Q39778606-E191329F-FA65-4B8B-8836-44D645AE67DC

Q39778606-ECEBADC1-B966-4AEB-90CD-B8A8DECCE7C1

Q39778606-F81A0A2B-CB3F-45E4-BF20-57A0DE41C475

P2860

Q39778606-049AEE15-F441-44BC-9906-47EEF08D1BA4

Q39778606-1895CBFD-44F0-4591-A9C8-95DC9F2FB63E

Q39778606-19F5B050-CD6E-4A2E-8643-48EA1B47226A

Q39778606-272FD105-FE37-41E5-B849-2856FBDAB626

Q39778606-31F05351-DC4C-4868-85CF-C3ED756241CE

Q39778606-405A4155-ECA8-4AE1-AAD6-33C25C34EDFA

Q39778606-43EDD4CD-2F45-43BF-ADDA-4F2ECFE36932

Q39778606-45FECF27-F741-402C-B525-D130DC86DD0D

Q39778606-4EB2B370-1C68-4C34-A04F-966A0BB15B79

Q39778606-5A8E2417-5F54-454A-B063-C652401ED922

P304

Q39778606-4E5AA0E3-F860-4323-91C5-812407943768

P31

Q39778606-752CE8D1-85A5-435B-B084-B74B9027F23F

P356

Q39778606-8C7128D3-4B80-4589-94C0-3168199F4EFE

P407

Q39778606-A4D9DD48-96B6-42BA-8A51-07D0B404FF9B

P433

Q39778606-5AA5DD19-3E43-41F8-9180-77936CD93680

P478

Q39778606-DA9B808A-C936-4FC8-9F8F-3288C9296EFA

P50

Q39778606-FB57DB89-874A-4707-A6DB-4FA3F97EA330

P577

Q39778606-35545E4A-42B8-4C20-BA0C-C2C9DF5773C1

P5875

Q39778606-12D9F0A3-7FAC-4387-84D7-791C8B48BD1A

P698

Q39778606-874723E9-FAF4-40EE-BF97-E7F9AF09BE9A

P921

Q39778606-092B120A-B53E-4E26-BB6B-E69CBC9CE5A6

Q39778606-56FA8338-2661-4958-A395-11D8CDC596CE

P932

Q39778606-08B5B7B9-A9B4-4A47-A799-9814A3A725D1

P356

P1433

P1476

Inhibition of monocyte adhesio ...... -1 receptor agonist, exendin-4

@en

P2093

Chie Ebato

http://www.w3.org/2001/XMLSchema#string

Hiromasa Goto

http://www.w3.org/2001/XMLSchema#string

Kosuke Azuma

http://www.w3.org/2001/XMLSchema#string

Masayuki Arakawa

http://www.w3.org/2001/XMLSchema#string

Ryuzo Kawamori

http://www.w3.org/2001/XMLSchema#string

Takahisa Hirose

http://www.w3.org/2001/XMLSchema#string

Takashi Nomiyama

http://www.w3.org/2001/XMLSchema#string

Tomoya Mita

http://www.w3.org/2001/XMLSchema#string

Yoshio Fujitani

http://www.w3.org/2001/XMLSchema#string

P2860

The NR4A orphan nuclear receptor NOR1 is induced by platelet-derived growth factor and mediates vascular smooth muscle cell proliferation

Atherosclerosis — An Inflammatory Disease

A major role for VCAM-1, but not ICAM-1, in early atherosclerosis

Biology of incretins: GLP-1 and GIP

Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit nuclear factor-kappa B-dependent gene activation at multiple levels in the human monocytic cell line THP-1.

Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system.

Impact of oxidative stress and peroxisome proliferator-activated receptor gamma coactivator-1alpha in hepatic insulin resistance.

A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules.

Cutting edge: macrophage inhibition by cyclic AMP (cAMP): differential roles of protein kinase A and exchange protein directly activated by cAMP-1.

The beta-adrenoceptor agonist clenbuterol is a potent inhibitor of the LPS-induced production of TNF-alpha and IL-6 in vitro and in vivo.

P304

1030-1037

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DB09-1694

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

59

http://www.w3.org/2001/XMLSchema#string

P50

Hirotaka Watada

P577

2010-01-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41000803

http://www.w3.org/2001/XMLSchema#string

P698

20068138

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis

P932

2844811

http://www.w3.org/2001/XMLSchema#string